Roche announces $7.1bn deal to acquire Telavant and RVT-3101 antibody

Switzerland-based Roche has officially declared its acquisition agreement for Telavant Holdings, Inc., a Roivant company collaboratively owned by Roivant Sciences Ltd. and Pfizer Inc. The ... Read More